Neuroimaging Biomarkers Across the Dementia Spectrum
Tuesday April 25, 2017 7:00 am to 9:00 am
Aging, Dementia, Cognitive, and Behavioral Neurology
Liana Apostolova MD, FAAN
Faculty will update clinicians on the newest vivo methods to detect AD pathology in the brain; review all major modalities for imaging of neurodegenerative disorders and their applications in the clinic and research; discuss barriers to using amyloid radiotracers in the diagnostic evaluation of Alzheimer's and mild cognitive impairment, and ongoing efforts to overcome these barriers; and cover how these new biomarkers can help us understand the heterogeneity of neurodegeneration, and help us improve therapeutic outcomes.
Participants should be able to understand the role imaging methods play in the evaluation of neurodegenerative diseases; gain knowledge of the specific imaging biomarker signatures of the major classes of neurodegenerative diseases; understand how biomarkers can be used in conjunction with clinical findings to refine the differential diagnosis; understand how biomarkers may be used in the future to facilitate targeted therapies; and understand the barriers for using amyloid imaging in clinical settings, and the ongoing approaches to rectify those barriers.
Medical Knowledge, Patient Care, Systems-Based Practice
Program Speakers - Tentative
7:00 AM - 7:40 AM
Updates on the Clinical and Research Use of Magnetic Resonance Imaging in Neurodegenerative Disorders
Liana Apostolova MD, FAAN
7:40 AM - 8:20 AM
The Role of Functional Neuroimaging in the Evaluation of Patients with Cognitive/Behavioral Impairment or Dementia
Bradford Dickerson MD
8:20 AM - 9:00 AM
Towards Molecular Diagnosis: Clinical Applications of Amyloid and Tau PET Imaging
Gil Dan Rabinovici MD
Liana Apostolova, MD, FAAN
Dr. Apostolova has nothing to disclose.
Bradford Dickerson, MD
Dr. Dickerson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Lilly, Biogen and Piramal. Dr. Dickerson has received personal compensation in an editorial capacity for Neuroimage.
Gil Dan Rabinovici, MD
Dr. Rabinovici has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech and Merck. Dr. Rabinovici has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Rabinovici has received research support from Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare and Piramal.
Ready to register for the 2018 AAN Annual Meeting?